Back to Search
Start Over
Discovery of novel pyridinones as MGAT2 inhibitors for the treatment of metabolic disorders.
- Source :
-
Bioorganic & medicinal chemistry letters [Bioorg Med Chem Lett] 2023 Jul 15; Vol. 91, pp. 129362. Date of Electronic Publication: 2023 Jun 08. - Publication Year :
- 2023
-
Abstract
- Inhibition of monoacylglycerol transferase 2 (MGAT2) has recently emerged as a potential therapeutic strategy for the treatment of metabolic diseases such as obesity, diabetes and non-alcoholic steatohepatitis (NASH). Metabolism studies with our clinical lead (1) suggested variability in in vitro glucuronidation rates in liver microsomes across species, which made projection of human doses challenging. In addition, the observation of deconjugation of the C3-C4 double bond in the dihydropyridinone ring of 1 in solution had the potential to complicate its clinical development. This report describes our lead optimization efforts in a novel pyridinone series, exemplified by compound 33, which successfully addressed both of these potential issues.<br />Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.<br /> (Copyright © 2023 Elsevier Ltd. All rights reserved.)
Details
- Language :
- English
- ISSN :
- 1464-3405
- Volume :
- 91
- Database :
- MEDLINE
- Journal :
- Bioorganic & medicinal chemistry letters
- Publication Type :
- Academic Journal
- Accession number :
- 37295614
- Full Text :
- https://doi.org/10.1016/j.bmcl.2023.129362